
Corcept Therapeutics (CORT) Stock Forecast & Price Target
Corcept Therapeutics (CORT) Analyst Ratings
Bulls say
Corcept Therapeutics is a strong investment opportunity due to its positive international sales growth, recent CHMP recommendation for EU approval of Lifyorli, and planned relacorilant NDA resubmission for Cushing's syndrome. These factors, along with increased physician awareness and early adoption of Lifyorli in the US, suggest potential for significant market expansion globally and a favorable benefit-risk profile.
Bears say
Corcept Therapeutics is expected to see an increase in its stock price due to its strong financials, including positive revenue guidance of $1B at the midpoint, record starts for Korlym patients, and the successful completion of the pharmacy transition. Additionally, the company's pipeline has promising potential for treating serious disorders, providing an avenue for future growth. However, there are risks involved in the stock, such as potential commercial, clinical, and regulatory setbacks, as well as legal and intellectual property issues within the industry.
This aggregate rating is based on analysts' research of Corcept Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Corcept Therapeutics (CORT) Analyst Forecast & Price Prediction
Start investing in Corcept Therapeutics (CORT)
Order type
Buy in
Order amount
Est. shares
0 shares